Treating Duchenne means hope to
share meaningful moments

All photos here represent real VILTEPSO patients and compensated spokespeople

Duchenne muscular dystrophy (DMD) is caused by not having enough dystrophin. VILTEPSO is an exon-skipping therapy that has been granted accelerated approval based on its demonstrated increase in dystrophin in patients with DMD amenable to exon 53 skipping. Preliminary results from a Phase 3 confirmatory study of VILTEPSO have been received and are undergoing analysis and discussion with the FDA.

Stylized icon representing a caregiver figure, often used in patient support contexts.

If you are aHEALTHCARE PROVIDERwho treats patients with DMD

Learn More
Blue icon showing outline of a young child's head, typically used for user or demographic identifiers.

If you are aPATIENT or a CAREGIVERof a person with DMD

Discover VILTEPSO
Icon of an IV infusion pole, commonly used to indicate intravenous treatment or hospital care.

If you areLOOKING FOR SUPPORT and RESOURCES

Get Information

Providing personalized access support and customized resources

NS Pharma is fully committed to providing ongoing support to DMD patients, their caregivers, and healthcare professionals.

Learn About NS Support
Prescribing Information
News Release
Stay Informed
Gray arrow used to indicate Important Safety Information section. EXPAND

Indication

VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Important Safety Information

  • In clinical studies, no patients experienced kidney toxicity during treatment with VILTEPSO. However, kidney toxicity from drugs like VILTEPSO may be possible. Your doctor may monitor the health of your kidneys before starting and during treatment with VILTEPSO.
  • Common side effects include upper respiratory tract infection, injection site reaction, cough, and fever.
  • You are encouraged to report adverse events related to VILTEPSO. To do so, or for general inquiries, please call NS Pharma Medical Information at 1-866-NSPHARM (1-866-677-4276).

For more information about VILTEPSO, see full Prescribing Information.

For more information about VILTEPSO, see full Prescribing Information.